Allogeneic hematopoietic cell transplant for multiple myeloma using reduced intensity conditioning therapy, 1998–2006: factors associated with improved survival outcome-Reference-Cited by-同舟云学术

Allogeneic hematopoietic cell transplant for multiple myeloma using reduced intensity conditioning therapy, 1998–2006: factors associated with improved survival outcome

Published:2011-08-24 Issue:9 Volume:52 Page:1727-1735
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Nivison-Smith Ian,Dodds Anthony J.,Doocey Richard,Ganly Peter,Gibson John,Ma David D. F.,Simpson Judy M.,Szer Jeff,Bradstock Kenneth F.

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2011.582201

Reference26 articles.

1. Multiple myeloma

2. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome

3. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres

4. Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma

5. Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Allogeneic stem-cell transplantation for multiple myeloma: a systematic review and meta-analysis from 2007 to 2017;Cancer Cell International;2018-04-23

2. Hematopoietic Stem Cell Transplantation for Multiple Myeloma;Seminars in Oncology Nursing;2017-08

3. Trends and Outcomes in Allogeneic Hematopoietic Stem Cell Transplant for Multiple Myeloma at Mayo Clinic;Clinical Lymphoma Myeloma and Leukemia;2015-06

4. Outcomes of allogeneic haemopoietic stem cell transplants at a small New Zealand centre: does size matter?;Internal Medicine Journal;2014-07

5. A Randomized Phase II Trial of Fludarabine/Melphalan 100 versus Fludarabine/Melphalan 140 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma;Biology of Blood and Marrow Transplantation;2013-10